Andresa Rossilho Casale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andresa Rossilho Casale has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Gualano
Universidade de São Paulo
5 shared publications - Hamilton Roschel
Universidade de São Paulo
5 shared publications - Bruna Caruso Mazzolani
Universidade de São Paulo
2 shared publications - Danilo Reis Coimbra
UFJF, Brasil
2 shared publications - Igor Longobardi
Universidade de São Paulo
2 shared publications - Jose Davi Fajardo Villela Martins Pompilio da Hora
School of Medicine, University of Sao Paulo, Institute of Psychiatry, Clinical Hospital, Sao Paulo, SP, Brazil
2 shared publications
Latest Publications
- 17 August 2026
- Published by Springer Nature in European Journal of Applied Physiology
- Vol. 126 (10) , 5107-5110
The uncontrolled rise of performance peptides: reasons for concern and a call for scientific and regulatory action
- 17 August 2026
- Published by Springer Nature in European Journal of Applied Physiology
- Vol. 126 (10) , 5107-5110
The uncontrolled rise of performance peptides: reasons for concern and a call for scientific and regulatory action
- Top Cited Papers
- 3 February 2026
- Published by BMJ in British Journal of Sports Medicine
- Vol. 60 (3) , 198-210
Body composition and physical fitness in transgender versus cisgender individuals: a systematic review with meta-analysis
Objective: To compare body composition and physical fitness between transgender and cisgender individuals. Design: Systematic review with meta-analysis. Data sources: PubMed, Web of Science, Embase and SportDiscus. Eligibility criteria: Inclusion criteria comprised studies of transgender individuals comparing body composition or physical fitness pre-to-post gender-affirming hormone therapy (GAHT) or versus cisgender controls. Results: 50 studies (n=6099) were included. Transgender women had similar relative fat mass (standardised mean difference (SMD) −0.29, 95% CI −0.63 to 0.05, Grading of Recommendations Assessment, Development and Evaluation (GRADE): very low), relative lean mass (SMD 0.19, 95% CI −0.14 to 0.53, GRADE: low), upper-body strength (SMD 0.92, 95% CI −0.52 to 2.35, GRADE: very low), lower-body strength (SMD −0.10, 95% CI −1.07 to 0.86, GRADE: very low) and maximal oxygen consumption (SMD −0.28, 95% CI −0.81 to 0.25, GRADE: very low) in comparison to cisgender women. Transgender men exhibited higher relative fat mass (SMD 1.09, 95% CI 0.66 to 1.53, GRADE: moderate), lower relative lean mass (SMD −6.42, 95% CI −12.26 to −0.58, GRADE: moderate) and lower upper-body strength (SMD −1.20, 95% CI −1.96 to −0.45, GRADE: moderate) than cisgender men. In transgender women, GAHT was associated with increased fat mass and reduced lean mass and upper-body strength over 1–3 years. Transgender men demonstrated reduced fat mass and increased lean mass and strength following GAHT. Conclusion: While transgender women exhibited higher lean mass than cisgender women, their physical fitness was comparable. Current evidence is mostly low certainty and has heterogenous quality but does not support theories of inherent athletic advantages for transgender women over cisgender. PROSPERO registration number: CRD42024562210.
- 3 February 2026
- Published by BMJ in British Journal of Sports Medicine
- Vol. 60 (3) , 198-210
Top Cited PapersBody composition and physical fitness in transgender versus cisgender individuals: a systematic review with meta-analysis
Objective: To compare body composition and physical fitness between transgender and cisgender individuals. Design: Systematic review with meta-analysis. Data sources: PubMed, Web of Science, Embase and SportDiscus. Eligibility criteria: Inclusion criteria comprised studies of transgender individuals comparing body composition or physical fitness pre-to-post gender-affirming hormone therapy (GAHT) or versus cisgender controls. Results: 50 studies (n=6099) were included. Transgender women had similar relative fat mass (standardised mean difference (SMD) −0.29, 95% CI −0.63 to 0.05, Grading of Recommendations Assessment, Development and Evaluation (GRADE): very low), relative lean mass (SMD 0.19, 95% CI −0.14 to 0.53, GRADE: low), upper-body strength (SMD 0.92, 95% CI −0.52 to 2.35, GRADE: very low), lower-body strength (SMD −0.10, 95% CI −1.07 to 0.86, GRADE: very low) and maximal oxygen consumption (SMD −0.28, 95% CI −0.81 to 0.25, GRADE: very low) in comparison to cisgender women. Transgender men exhibited higher relative fat mass (SMD 1.09, 95% CI 0.66 to 1.53, GRADE: moderate), lower relative lean mass (SMD −6.42, 95% CI −12.26 to −0.58, GRADE: moderate) and lower upper-body strength (SMD −1.20, 95% CI −1.96 to −0.45, GRADE: moderate) than cisgender men. In transgender women, GAHT was associated with increased fat mass and reduced lean mass and upper-body strength over 1–3 years. Transgender men demonstrated reduced fat mass and increased lean mass and strength following GAHT. Conclusion: While transgender women exhibited higher lean mass than cisgender women, their physical fitness was comparable. Current evidence is mostly low certainty and has heterogenous quality but does not support theories of inherent athletic advantages for transgender women over cisgender. PROSPERO registration number: CRD42024562210.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 329 (6) , E849-E860
Interleukin-6 blockade does not impair exercise-induced glucose uptake and insulin sensitivity in rheumatoid arthritis
A single session of aerobic exercise has a similar effect on insulin sensitivity and muscle glucose uptake in women with RA treated with either IL-6i or TNF-αi. The study supports exercise as a safe and complementary strategy for patients with RA on IL-6i or TNF-αi therapy, reinforcing its inclusion in clinical care and the need for further research on long-term outcomes.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 329 (6) , E849-E860
Interleukin-6 blockade does not impair exercise-induced glucose uptake and insulin sensitivity in rheumatoid arthritis
A single session of aerobic exercise has a similar effect on insulin sensitivity and muscle glucose uptake in women with RA treated with either IL-6i or TNF-αi. The study supports exercise as a safe and complementary strategy for patients with RA on IL-6i or TNF-αi therapy, reinforcing its inclusion in clinical care and the need for further research on long-term outcomes.
- Open Access
- 3 November 2025
- Published by Wiley in Scandinavian Journal of Medicine & Science in Sports
- Vol. 35 (11) , e70160
Safety of Percutaneous Muscle Biopsy: An Update Based on Over 2400 Procedures
This study assessed the safety of percutaneous muscle biopsy by analyzing over 2400 procedures performed between 2007 and 2025 in healthy individuals and patients with chronic diseases. We retrospectively reviewed biopsy‐related adverse events among 1246 participants (471 healthy adults and 775 patients) to investigate whether health status or repeated sampling at the same site influenced complication rates. A total of 2435 biopsies were performed, primarily on the vastus lateralis muscle (97%). Overall, 80.6% of the procedures had no adverse events. The most common adverse events were erythema (6.6%), ecchymosis (4.1%), and pain (3.9%). Serious complications, including loss of consciousness (vasovagal syncope), were extremely rare (≤ 0.04%). Most adverse events occurred in isolation (74.9%) and did not preclude participation in subsequent research activities. Repeated biopsies modestly increased the risk of minor adverse events, particularly bleeding, erythema, and bruising. Notably, these were more frequently reported among healthy volunteers than among patients. In conclusion, percutaneous muscle biopsy is a safe and well‐tolerated procedure, even when performed repeatedly or in individuals with chronic diseases. The minor adverse events were infrequent, transient, and clinically manageable. These findings support the continued use of this technique in both research and clinical settings.
- 3 November 2025
- Published by Wiley in Scandinavian Journal of Medicine & Science in Sports
- Vol. 35 (11) , e70160
Open AccessSafety of Percutaneous Muscle Biopsy: An Update Based on Over 2400 Procedures
This study assessed the safety of percutaneous muscle biopsy by analyzing over 2400 procedures performed between 2007 and 2025 in healthy individuals and patients with chronic diseases. We retrospectively reviewed biopsy‐related adverse events among 1246 participants (471 healthy adults and 775 patients) to investigate whether health status or repeated sampling at the same site influenced complication rates. A total of 2435 biopsies were performed, primarily on the vastus lateralis muscle (97%). Overall, 80.6% of the procedures had no adverse events. The most common adverse events were erythema (6.6%), ecchymosis (4.1%), and pain (3.9%). Serious complications, including loss of consciousness (vasovagal syncope), were extremely rare (≤ 0.04%). Most adverse events occurred in isolation (74.9%) and did not preclude participation in subsequent research activities. Repeated biopsies modestly increased the risk of minor adverse events, particularly bleeding, erythema, and bruising. Notably, these were more frequently reported among healthy volunteers than among patients. In conclusion, percutaneous muscle biopsy is a safe and well‐tolerated procedure, even when performed repeatedly or in individuals with chronic diseases. The minor adverse events were infrequent, transient, and clinically manageable. These findings support the continued use of this technique in both research and clinical settings.
- Open Access
Physical Fitness and Body Composition in Transgender vs. Cisgender Individuals: A Systematic Review and Meta-Analysis
Objective: To compare fitness and body composition between transgender and cisgender individuals. Design: Systematic review and meta-analysis. Data sources: PubMed, Web of Science, Embase, and SportDiscus databases were searched in June 2024, supplemented by manual citation reviews. Eligibility criteria: Inclusion criteria comprised studies of transgender individuals comparing physical fitness/body composition pre-to-post gender-affirming hormone therapy (GAHT) or vs. cisgender controls, with quantitative outcomes reported. Results: Fifty-one studies (6,434 participants) were analyzed. Transgender women (TW) exhibited comparable fat mass to cisgender women (CW), but higher than cisgender men (CM). TW showed greater lean mass than CW, but lower than CM. Upper- and lower-body strength were similar between TW and CW, but lower than CM. TW and CW had similar VO 2 peak, but TW exhibited lower values than CM. Transgender men (TM) exhibited similar fat mass to CW, but higher than CM. TM showed higher lean mass than CW, but lower than CM. Upper-body strength was higher in TM than CW, but lower than CM. GAHT in TW increased fat mass, reduced lean mass and upper-body strength, with no differences in lower-body strength over 1–3 years. TM demonstrated reduced fat mass and increased lean mass, upper- and lower-body strength post-GAHT. Risk of bias was moderate for most studies, with limited observations for specific outcomes (e.g., VO 2 peak). Conclusion: While TW exhibited higher lean mass than CW, their physical fitness was comparable. Current evidence is limited but does not justify blanket bans based on assumptions of inherent athletic advantages for TW over CW. WHAT IS ALREADY KNOWN ON THIS TOPIC: The inclusion of transgender women in female sports categories remains a highly contentious subject. Existing studies suggest that gender-affirming hormone therapy (GAHT) alters body composition in transgender individuals, but evidence on functional performance outcomes (e.g., strength, endurance) remains inconsistent. Policies advocating blanket bans on transgender women (TW) in female sports often cite residual advantages from prior testosterone exposure, despite limited empirical support for sustained performance disparities post-GAHT. WHAT THIS STUDY ADDS?: This systematic review and meta-analysis synthesizes data from 51 studies (6,434 participants), demonstrating that, while TW showed higher absolute lean mass than cisgender women (CW), there are no significant differences in upper/lower-body strength or VO□peak after 1–3 years of GAHT. These findings challenge the validity of blanket bans predicated on assumptions of inherent athletic superiority of TW over CW. Transgender men (TM) exhibit body composition and strength metrics intermediate between CW and cisgender men (CM) post-GAHT. Critical research gaps are identified, including a lack of long-term GAHT data, underrepresentation of transgender athletes, and inconsistent controls for confounders (e.g., training history, puberty blocking). Future studies must prioritize sport-specific performance metrics and longitudinal designs to inform equitable policies.
Open AccessPhysical Fitness and Body Composition in Transgender vs. Cisgender Individuals: A Systematic Review and Meta-Analysis
Objective: To compare fitness and body composition between transgender and cisgender individuals. Design: Systematic review and meta-analysis. Data sources: PubMed, Web of Science, Embase, and SportDiscus databases were searched in June 2024, supplemented by manual citation reviews. Eligibility criteria: Inclusion criteria comprised studies of transgender individuals comparing physical fitness/body composition pre-to-post gender-affirming hormone therapy (GAHT) or vs. cisgender controls, with quantitative outcomes reported. Results: Fifty-one studies (6,434 participants) were analyzed. Transgender women (TW) exhibited comparable fat mass to cisgender women (CW), but higher than cisgender men (CM). TW showed greater lean mass than CW, but lower than CM. Upper- and lower-body strength were similar between TW and CW, but lower than CM. TW and CW had similar VO 2 peak, but TW exhibited lower values than CM. Transgender men (TM) exhibited similar fat mass to CW, but higher than CM. TM showed higher lean mass than CW, but lower than CM. Upper-body strength was higher in TM than CW, but lower than CM. GAHT in TW increased fat mass, reduced lean mass and upper-body strength, with no differences in lower-body strength over 1–3 years. TM demonstrated reduced fat mass and increased lean mass, upper- and lower-body strength post-GAHT. Risk of bias was moderate for most studies, with limited observations for specific outcomes (e.g., VO 2 peak). Conclusion: While TW exhibited higher lean mass than CW, their physical fitness was comparable. Current evidence is limited but does not justify blanket bans based on assumptions of inherent athletic advantages for TW over CW. WHAT IS ALREADY KNOWN ON THIS TOPIC: The inclusion of transgender women in female sports categories remains a highly contentious subject. Existing studies suggest that gender-affirming hormone therapy (GAHT) alters body composition in transgender individuals, but evidence on functional performance outcomes (e.g., strength, endurance) remains inconsistent. Policies advocating blanket bans on transgender women (TW) in female sports often cite residual advantages from prior testosterone exposure, despite limited empirical support for sustained performance disparities post-GAHT. WHAT THIS STUDY ADDS?: This systematic review and meta-analysis synthesizes data from 51 studies (6,434 participants), demonstrating that, while TW showed higher absolute lean mass than cisgender women (CW), there are no significant differences in upper/lower-body strength or VO□peak after 1–3 years of GAHT. These findings challenge the validity of blanket bans predicated on assumptions of inherent athletic superiority of TW over CW. Transgender men (TM) exhibit body composition and strength metrics intermediate between CW and cisgender men (CM) post-GAHT. Critical research gaps are identified, including a lack of long-term GAHT data, underrepresentation of transgender athletes, and inconsistent controls for confounders (e.g., training history, puberty blocking). Future studies must prioritize sport-specific performance metrics and longitudinal designs to inform equitable policies.